Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-blind, Placebo-controlled Phase II Trial (MAyflOwer RoAD)

Manuscript Number: 

16-1309R1

Author(s): 
Mercè Boada, Edilio Borroni, Tracie Carey, Christian Czech, Paul Delmar, Rachelle S. Doody, Juergen Dukart, Paulo Fontoura, Irene Gerlach, Inma Gilaberte, Timo Grimmer, Marie Mannino, Nicoletta Milani Muelhardt, Emma Moran, Stephane Nave, Tania Nikolcheva, Susanne Ostrowitzki, Meike Pauly-Evers, Benedicte Ricci, Luca Santarelli, Juha-Matti Savola

Disclosures

Mercè Boada

  • Consulting Fees:
    Dr. M. Boada has consulted for Araclon, Avid, Bayer, Elan, Grifols, Janssen/Pfizer, Lilly, MSD, Nutricia, Roche, Sanofi, and Servier.
    Lecture Fees:
    She received fees for lectures and funds for research from Araclon, Grifols, Merck, Novartis, Nutricia, Piramal, Roche, and Servier.
    Grants
    • Agency: 
      EFSD - European Foundation for the Study of Diabetes. EFSD/Lilly Mental Health and Diabetes Programme.
      Dates: 
      2014-2015

Edilio Borroni

  • Sponsors:
    I am a full time employee of Hoffmann-La Roche Ltd. I am currently working in the CNS Biomarker group.

Tracie Carey

  • Equity:
    As an employee of Roche, I am awarded stock options and stock as part of a long-term incentives plan. Currently I hold 79 shares and stock options which are worth a little over $12,000 US as of April 20,2017. I have other options and stock units in my account which are not yet vested. I hold about 100 shares of Teva Pharmaceuticals stock.
    Sponsors:
    I am a full-time employee of Roche located at the Roche Innovation Center, New York, USA

Christian Czech

  • Equity:
    Member of the Roche employees stock program
    Sponsors:
    Full time employee of Roche

Paul Delmar

  • Equity:
    F. Hoffmann - La Roche Ltd.
    Sponsors:
    Full Time Employee - F. Hoffmann-La Roche Ltd.

Rachelle S. Doody

  • Equity:
    Stock options in Roche and AZ Therapies
    Sponsors:
    At the time of the study, I was working at Baylor College of Medicine, but am now employed by Roche

Juergen Dukart

  • Sponsors:
    regular employee

Paulo Fontoura

  • Equity:
    Stock ownership in F Hoffmann-La Roche
    Sponsors:
    Current employee of F Hoffmann-La Roche

Irene Gerlach

  • Equity:
    less than 500 shares in Novartis les than 500 shares and stock options in Roche (study sponsor)
    Sponsors:
    Project Leader in Neuroscience Development

Inma Gilaberte

  • Sponsors:
    I was clinical director at the time the study was finalized

Timo Grimmer

  • Consulting Fees:
    Consulting fees from Actelion, Eli Lilly, MSD; Novartis, Quintiles, Roche Pharma
    Lecture Fees:
    Lecture fees from Biogen, Lilly, Parexel, Roche Pharma

Marie Mannino

  • Equity:
    I own Roche stock
    Sponsors:
    I work for Roche Pharmaceuticals, the sponsor of the study.

Nicoletta Milani Muelhardt

  • Sponsors:
    Full time employee by Hoffman La Roche, Basel

Emma Moran

  • Equity:
    I own some Roche shares
    Sponsors:
    Full time employee of Roche Products UK

Stephane Nave

  • Sponsors:
    Clinical Science Leader , regular employee at F-Hoffmann La-Roche Basel, Switzerland

Tania Nikolcheva

  • Equity:
    Roche stock and stock options
    Sponsors:
    Full time employee of F. Hoffmann-La Roche

Susanne Ostrowitzki

  • Equity:
    Stock ownership in F. Hoffmann-La Roche Ltd
    Sponsors:
    Clinical Development

Meike Pauly-Evers

  • Equity:
    Roche Non-Voting Equity Securities - Currency: CHF - Code: ROG.VX
    Sponsors:
    Clinical Scientist at Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Switzerland

Benedicte Ricci

  • Equity:
    Roche stock program for employees : Stock-settled Stock appreciation rights and restricted stock units, granted value in 2016: 17,000 CHF
    Sponsors:
    Clinical pharmacologist at F.Hoffmann-LaRoche

Luca Santarelli

  • Sponsors:
    Employed by Roche when the study was conducted

Juha-Matti Savola

  • Equity:
    Both equity and stock options in F. Hoffmann-La Roche Ltd
    Sponsors:
    Full-time employment as project leader at F. Hoffmann-La Roche Ltd